Abstract
In recent years the anticancer properties of vanadium compounds have been noticed, but the underlying mechanisms are not well understood. In the present work, we found that vanadyl bisacetylacetonate ([VO(acac)2]) blocked cell cycle progression permanently at G1 phase in a dose- and time-dependent manner in HepG2 cells. This was further evidenced by the growth regulatory signals during the G1 stage. After the treatment with [VO(acac)2], the level of phophorylation of retinoblastoma tumor suppressor protein (pRb) and the expressions of cyclin D1, cyclin E and cyclin A were reduced, while the expression of a cyclin-dependent kinase inhibitor p21 was increased dose-dependently. In the meantime, neither O2 •− nor H2O2 level was observed to increase. Interestingly, the levels of phosphorylated extracellular signal-regulated protein kinase (ERK) and Akt were highly activated. After 1-h pretreatment with a lower concentration of MEK inhibitor U0126, the level of phosphorylated pRb was restored, indicating a release of cell cycle arrest. Taken together, we suggested that [VO(acac)2]-induced proliferation inhibition was caused by G1/S cell cycle arrest, which resulted from the decreased level of phosphorylated pRb in its active hypophosphorylated form via a highly activated ERK signal in HepG2 cells. The results presented here provided new insight into the development of vanadium compounds as potential anticancer agents.
Similar content being viewed by others
Abbreviations
- DCFH-DA:
-
2,7-Dichlorofluorescein diacetate
- ERK:
-
Extracellular signal-regulated protein kinase
- FBS:
-
Fetal bovine serum
- HE:
-
Dihydroethidium
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
Mitogen-activated protein kinase
- MEM:
-
Minimum essential medium
- MTT:
-
3-(4,5-Dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide
- PBS:
-
Phosphate-buffered saline
- PI3-K:
-
Phosphatidylinositol 3-kinase
- pRb:
-
Retinoblastoma tumor suppressor protein
- ROS:
-
Reactive oxygen species
- Tris:
-
Tris(hydroxymethyl)aminomethane
- [VO(acac)2]:
-
Vanadyl bisacetylacetonate
- [VO(ma)2]:
-
Vanadyl bismaltolate
References
Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y (2000) J Inorg Biochem 80:21–25
Shechter Y, Li J, Meyerovitch J, Gefel D, Bruck R, Elberg G, Miller DS, Shisheva A (1995) Mol Cell Biochem 153:39–47
Srivastava AK, Mehdi MZ (2005) Diabet Med 22:2–13
Srivastava AK (2000) Mol Cell Biochem 206:177–182
Evangelou AM (2002) Crit Rev Oncol Hematol 42:249–265
Desoize B (2004) Anticancer Res 24:1529–1544
Sun RW, Ma DL, Wong EL, Che CM (2007) Dalton Trans 4884–4892
Goc A (2006) Cent Eur J Biol 1:314–332
Tang H, Sun Y, Xiu Q, Lu H, Han H (2007) Arch Biochem Biophys 468:92–99
Zhang Z, Gao N, He H, Huang C, Luo J, Shi X (2004) Mol Cell Biochem 255:227–237
Chien PS, Mak OT, Huang HJ (2006) Biochem Biophys Res Commun 339:562–568
Ray RS, Ghosh B, Rana A, Chatterjee M (2007) Int J Cancer 120:13–23
Hanauske U, Hanauske AR, Marshall MH, Muggia VA, Von Hoff DD (1987) Int J Cell Cloning 5:170–178
Shioda N, Ishigami T, Han F, Moriguchi S, Shibuya M, Iwabuchi Y, Fukunaga K (2007) Neuroscience 148:221–229
Molinuevo MS, Barrio DA, Cortizo AM, Etcheverry SB (2004) Cancer Chemother Pharmacol 53:163–172
Ding M, Li JJ, Leonard SS, Ye JP, Shi X, Colburn NH, Castranova V, Vallyathan V (1999) Carcinogenesis 20:663–668
Zhang Z, Leonard SS, Huang C, Vallyathan V, Castranova V, Shi X (2003) Free Radic Biol Med 34:1333–1342
Zhang Z, Huang C, Li J, Leonard SS, Lanciotti R, Butterworth L, Shi X (2001) Arch Biochem Biophys 392:311–320
Zhang Z, Huang C, Li J, Shi X (2002) J Inorg Biochem 89:142–148
Ferrer EG, Salinas MV, Correa MJ, Naso L, Barrio DA, Etcheverry SB, Lezama L, Rojo T, Williams PA (2006) J Biol Inorg Chem 11:791–801
Cortizo AM, Molinuevo MS, Barrio DA, Bruzzone L (2006) Int J Biochem Cell Biol 38:1171–1180
Oliver SJ, Firestein GS, Arsenault L, Cruz TF, Cheng TP, Banquerigo ML, Boyle DL, Brahn E (2007) J Rheumatol 34:1802–1809
Zhang Z, He H, Chen F, Huang C, Shi X (2002) Chem Res Toxicol 15:950–956
Katherine H, Thompson, Orvig C (2000) J Chem Soc Dalton Trans 2885–2892
Yuen VG, Caravan P, Gelmini L, Glover N, McNeill JH, Setyawati IA, Zhou Y, Orvig C (1997) J Inorg Biochem 68:109–116
Crans DC (2000) J Inorg Biochem 80:123–131
Dai X, Cao X, Kreulen DL (2006) Am J Physiol Heart Circ Physiol 290:H1019–H1026
Doudican NA, Song B, Shadel GS, Doetsch PW (2005) Mol Cell Biol 25:5196–5204
Huber A, Thongphasuk P, Erben G, Lehmann WD, Tuma S, Stremmel W, Chamulitrat W (2008) Biochim Biophys Acta 1780:837–847
Tamrakar S, Rubin E, Ludlow JW (2000) Front Biosci 5:D121–D137
Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y (1996) EMBO J 15:7060–7069
Tsukada Y, Miyazawa K, Kitamura N (2001) J Biol Chem 276:40968–40976
Wang S, Liu S, Wu MH, Geng Y, Wood C (2001) J Virol 75:11961–11973
Garcia Z, Kumar A, Marques M, Cortes I, Carrera AC (2006) EMBO J 25:655–661
Meloche S, Pouyssegur J (2007) Oncogene 26:3227–3239
Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) Biochim Biophys Acta 1773:1299–1310
Sit KH, Paramanantham R, Bay BH, Chan HL, Wong KP, Thong P, Watt F (1996) Anat Rec 245:1–8
Sit KH, Paramanantham R, Bay BH, Wong KP, Thong P, Watt F (1996) Experientia 52:778–785
Sit KH, Yin L, Paramanantham R (1997) Anat Rec 248:149–158
Ahmed Ouameur A, Arakawa H, Tajmir-Riahi HA (2006) Biochem Cell Biol 84:677–683
Ye J, Ding M, Leonard SS, Robinson VA, Millecchia L, Zhang X, Castranova V, Vallyathan V, Shi X (1999) Mol Cell Biochem 202:9–17
Chakraborty T, Chatterjee A, Saralaya MG, Chatterjee M (2006) J Biol Inorg Chem 11:855–866
Chakraborty T, Swamy AH, Chatterjee A, Rana B, Shyamsundar A, Chatterjee M (2007) J Cell Biochem 101:244–258
Ray RS, Rana B, Swami B, Venu V, Chatterjee M (2006) Chem Biol Interact 163:239–247
Lapenna D, Ciofani G, Bruno C, Pierdomenico SD, Giuliani L, Giamberardino MA, Cuccurullo F (2002) Biochem Pharmacol 63:375–380
Leonard SS, Harris GK, Shi X (2004) Free Radic Biol Med 37:1921–1942
Capella MA, Capella LS, Valente RC, Gefe M, Lopes AG (2007) Cell Biol Toxicol 23:413–420
Barrio DA, Cattaneo ER, Apezteguia MC, Etcheverry SB (2006) Can J Physiol Pharmacol 84:765–775
Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T (2005) J Biol Chem 280:31548–31556
Burdon T, Smith A, Savatier P (2002) Trends Cell Biol 12:432–438
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) J Alzheimers Dis 7:63–80
Taguchi A, Wartschow LM, White MF (2007) Science 317:369–372
Li L, Holscher C (2007) Brain Res Rev 56:384–402
Sun MK, Alkon DL (2006) Timely Top Med Cardiovasc Dis 10:E24
Sima AA, Li ZG (2006) Rev Diabet Stud 3:161–168
Pilcher H (2006) Lancet Neurol 5:388–389
Mehdi MZ, Srivastava AK (2005) Arch Biochem Biophys 440:158–164
Acknowledgments
This work was supported by the National Natural Science Foundation of China (nos. 20637010 and 20671008) and by grants from the School of Pharmaceutical Sciences, Peking University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fu, Y., Wang, Q., Yang, XG. et al. Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells. J Biol Inorg Chem 13, 1001–1009 (2008). https://doi.org/10.1007/s00775-008-0387-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-008-0387-2